Other
Inflammatory Mediators
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Inflammatory Mediators is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
14
clinical trials
Completed10 · 71%
Suspended1 · 7%
Terminated1 · 7%
Unknown status1 · 7%
Withdrawn1 · 7%
Clinical Trials
Trial Activity
14 trials
Effect of Calcium Silicate Based Root Canal Medicament on Inflammatory Mediators
Completed·—·N/A·NCT06307678·60 enrolled
Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects
Completed·—·N/A·NCT00898222·4 enrolled
Role of Inflammatory Mediators in AERD
Completed·—·N/A·NCT02824523·40 enrolled
Effect of Garlic on Inflammatory Mediators
Suspended·—·Phase 4·NCT00275405·34 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)